Skip to main content
Mark Joseph Eliason
( out of 592 reviews )

Mark Joseph Eliason, MD

Languages spoken: English

Clinical Locations

  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Board Certification

    American Board of Dermatology (Dermatology)

    Patient Rating

    5.0 /5
    ( out of 592 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 25, 2023
    SUGAR HOUSE HEALTH CENTER

    My favorite doctor. He always is professional but filled with joy, expert, and patient.

    August 25, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Explained things in a way I understand and very through and caring.

    August 24, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    I would highly recommend Dr. Eliason to friends and family. He makes you feel very comfortable.

    August 24, 2023
    SUGAR HOUSE HEALTH CENTER

    My experience with Dr. Eliason is always positive, even though I have issues with skin that are not so positive. He treats me with great respect but in a very personal yet professional way; I feel heard by him when I have questions or concerns. I'm really blessed to have found him and that he was taking new patients.

    August 20, 2023
    SUGAR HOUSE HEALTH CENTER

    I hadn't seen Dr. Eliason for several years, but was treated as if I had been a longtime, regular patient. He has a great chairside manner and doesn't rush the exam or treatment. He is very communicative and easy talk to as well. I wouldn't hesitate to visit Dr. Eliason any time I might need a dermatologist in the future.

    August 18, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Very helpful & kind. Listened to my concerns and made suggestions that will work for me.

    August 17, 2023
    UH HOSPITALS AND CLINICS

    Dr. Eliason is the best (10/10)! He doesn't waste time, but I felt like he was 100% focused on my appointment while I was there, gentle and with a great sense of humor.

    August 17, 2023
    UH HOSPITALS AND CLINICS

    Dr. Eliason is always very thorough and really takes the time to answer my questions and concerns.

    August 16, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Eliason is the best! I think so highly of him!

  • Mark Eliason, MD has specialized interest in skin cancer and inflammatory diseases of the skin. He is board certified in dermatology. He has completed a two-year fellowship in familial melanoma genetics and published research in this area. In addition, he has interest in inflammatory diseases such as urticaria and eczema. He sees patients for any general dermatologic concerns.

    Board Certification and Academic Information

    Academic Departments Dermatology -Primary
    Board Certification
    American Board of Dermatology (Dermatology)

    Education history

    Residency Dermatology - University of Utah School of Medicine Resident
    Familial Melanoma - Huntsman Cancer Institute Research Fellow
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Medicine - University of California - Irvine M.D.
    Undergraduate Molecular Biology - Brigham Young University B.S.

    Selected Publications

    Journal Article

    1. Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA Dermatol, 156(10), 1074-1078. (Read full article)
    2. Forbes B, Secrest AM, Hand MQ, Eliason MJ (2018). Process of Post-operative Telephone Follow-up Implementation for Mohs Micrographic Surgery: A Pilot Study. J Clin Aesthet Dermatol, 11(7), 36-39. (Read full article)
    3. Clark JJ, Woodcock A, Cipriano SD, Hyde MA, Edwards SL, Frost CJ, Eliason MJ (2016). Community perceptions about the use of black salve. J Am Acad Dermatol, 74(5), 1021-3. (Read full article)
    4. Eliason MJ, Sontheimer RD (2015). How to reduce out-of-pocket costs for prescription medications.LID - 13030/qt5bk5n1vj [pii]. Dermatol Online J, 21(6). (Read full article)
    5. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD (2012). A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol, 67(4), 680-6. (Read full article)
    6. Pho LN, Eliason MJ, Regruto M, Hull CM, Powell DL (2011). Treatment of chronic urticaria with colchicine. J Drugs Dermatol, 10(12), 1423-8. (Read full article)
    7. Pho LN, Smith FJ, Konecki D, Bale S, McLean WH, Cohen B, Eliason MJ, Leachman SA (2011). Paternal germ cell mosaicism in autosomal dominant pachyonychia congenita. Arch Dermatol, 147(9), 1077-80. (Read full article)
    8. Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL (2011). Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol, 64(6), 1221-2. (Read full article)
    9. McLean WH, Hansen CD, Eliason MJ, Smith FJ (2011). The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol, 131(5), 1015-7. (Read full article)
    10. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6. (Read full article)
    11. Eliason MJ, Bowen GM, Bowen AR, Hazzard L, Samlowski WE (2009). Primary Treatment of Verrucous Carcinoma of the Penis with 5-fluorouracil, cis-diamino-dichloro platinum and Radiation Therapy Arch Derm). Arch Dermatol, 145(11), 1291.
    12. Larson AA, Leachman SA, Eliason MJ, Cannon-Albright LA (2007). Population-based assessment of non-melanoma cancer risk in relatives of cutaneous melanoma probands. J Invest Dermatol, 127(1), 183-8. (Read full article)
    13. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA (2006). Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol, 126(3), 660-6. (Read full article)

    Review

    1. Millsop JW, Heller MM, Eliason MJ, Murase JE (2013). Dermatological medication effects on male fertility. [Review]. Dermatol Ther, 26(4), 337-46. (Read full article)
    2. Leachman SA, Jackson R, Eliason MJ, Larson AA, Bolognia JL (2007). Management of melanoma during pregnancy. [Review]. Dermatol Nurs, 19(2), 145-52, 161. (Read full article)

    Case Report

    1. Eliason MJ, Hansen CB, Hart M, Porter-Gill P, Chen W, Sturm RA, Bowen G, Florell SR, Harris RM, Cannon-Albright LA, Swinyer L, Leachman SA (2007). Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. Arch Dermatol, 143(11), 1409-12. (Read full article)

    Letter

    1. Houston NA, Secrest AM, Harris RJ, Mori WS, Eliason MJ, Phillips CM, Ferris LK (2016). Patient Preferences During Skin Cancer Screening Examination. [Letter to the editor]. JAMA Dermatol, 152(9), 1052-4. (Read full article)
    2. Clark JJ, Secrest AM, Hull CM, Eliason MJ, Leiferman KM, Gleich GJ, Powell DL (2016). The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. [Letter to the editor]. J Am Acad Dermatol, 74(6), 1274-6. (Read full article)